AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02006719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: Treatment of Adhesive Capsulitis
Study NCT02006719 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study NCT02801383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yallaferon®， the recombinant human interferon α-2b gel
Study NCT02801383 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gel without active ingredient
Study NCT04115423 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: A humanized monoclonal antibody against the interleukin-6 receptor, which is mainly for the treatment of rheumatoid arthritis.
Study NCT04115423 — intervention group
Intervention type: DRUG
Intervention: Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)
Description: Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
Study NCT01499316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Flow oxygen
Description: 10 minute shigh flow oxygen
Study NCT01499316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Room Air
Description: Room air breathing
Study NCT04699058 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-antibody test
Description: Questionnaire and COVID-antibody test for all participants
Study NCT03562325 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy (ACT)
Description: The main target in ACT for ME/CFS (as for Fibromyalgia and Chronic pain in previous studies by our group) is to promote a shift of perspective in life from symptom reduction (when it does not work) to a valued life. As such it entails acceptance and exposure to discomfort, in order to lessen the effects of negative experiences (symptoms, emotions, thoughts) on behaviours in everyday life.
Study NCT02412605 — intervention group
Intervention type: PROCEDURE
Intervention: Trophectoderm embryo biopsy
Description: Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.~Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred.
Study NCT03566147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human primary Retinal Pigment Epithelial (HuRPE) cells
Description: HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.
Study NCT02044822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablets administered orally twice daily
Study NCT02044822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously once weekly x 8 weeks
Study NCT02528799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nexvax2
Description: Nexvax2 intra-dermal injections twice weekly
Study NCT02528799 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nexvax2 placebo
Description: Sodium chloride 0.9% intra-dermal injections twice weekly
Study NCT02870244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Escalating Doses
Description: Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.~Subjects in Cohort 1 will receive 7.5 x 10\^6/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 2 will receive 2.5 x 10\^7/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 3 will receive 7.5 x 10\^7/kg TIL 1383I TCR transduced T cells.
Study NCT05472376 — intervention group
Intervention type: OTHER
Intervention: Retrospective study
Description: Retrospective study
Study NCT05032287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin 0.4 mg once daily
Study NCT05032287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT03042195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Nutrition
Description: Supplementary parenteral nutrition to achieve 100% coverage of estimated needs
Study NCT00440141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops
Description: latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
Study NCT00440141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops
Description: latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
Study NCT02941198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GyneFix
Description: The fiber is fixed to the anchoring thread by means of a stainless steel clip 1 cm from the upper part of the anchoring knot. The anchoring knot is implanted into the myometrium of the uterus thus permanently securing the implant in the uterine cavity
Study NCT02941198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cu T380 A
Description: Cu T380 A will be inserted into the uterus
Study NCT01846416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Description: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
Study NCT00637338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04603629
Description: Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
Study NCT00637338 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
Study NCT02634671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: schizophrenia
Description: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
Study NCT02634671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the 22q11 deletion syndrome
Description: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
Study NCT02634671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
Study NCT03942172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpotOn balance glasses
Description: SpotOn Balance Glasses comprising of personalized visual stimuli placed on the glasses's lenses
Study NCT00938093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
Study NCT00938093 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced usual care
Description: Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
Study NCT02076243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
Study NCT04594304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Usual care plus eToolkit
Description: A baseline e-survey will be sent to participants prior to their scheduled appointment to collect baseline alcohol/tobacco use levels as well as a series of questions evaluating precursors to behaviour change. If randomized into the intervention group, patients will be sent a link to a tailored toolkit based on their behaviours, motivation to change and other pertinent factors. Patients who identify as non-smokers and meet the low-risk drinking guideline, will complete a third screening survey for physical activity. The cumulative patient profile (CPP) status for the patient for alcohol/smoking will be automatically updated post-baseline survey, and the PCP will receive a notification via EMR about the status update. For patients identifying with risky behaviours, the PCP will receive a prompt to update the CPP for the patient and will receive a link, embedded in the EMR, to a PCP-facing toolkit that facilitates evidence-based intervention.
Study NCT00787852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47
Description: Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily~Maintenance x 2 years\*
Study NCT00787852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
Description: Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily Maintenance x 2 years\*
Study NCT02714582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedside shift report
Description: Bedside shift report is a process where shift-to-shift report between nurses is, if approved by the patient, executed at the patient's bedside in order to improve the patient's involvement (Anderson \& Mangino 2006).
Study NCT03395860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: group A:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3 group B:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
Study NCT02924272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib Capsules
Study NCT00576368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
Study NCT03140657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Description: Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months
Study NCT03140657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
Study NCT02549521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral magnesium substitution
Description: The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
Study NCT00023504 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax
Description: To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
Study NCT00023504 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabavert
Description: To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
Study NCT02549521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets without magnesium
Description: The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
Study NCT00256646 — intervention group
Intervention type: DRUG
Intervention: Rosiglitazone
Description: ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
Study NCT04548479 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEP bottle
Description: PEP bottle: it will be performed with a bottle of distilled water and a plastic tube, where the patient breathes against a resistance during expiration.
Study NCT02822352 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy
Description: High definition virtual chromoendoscopy
Study NCT03334656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological dressing
Description: to test a biological dressing on the wound healing of the split-thickness skin graft donor site
Study NCT00753493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous topiramate
Description: Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
Study NCT05565508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new laparoscopic access technique for group a
Description: new laparoscopic access technique through the epigastric region
Study NCT03334656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin gauze dressing
Description: standard intervention : Paraffin gauze dressing on the wound healing
Study NCT02460172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip Surgical Skin Closure
Description: Non invasive, reversible, skin closure device for closure of the skin layer following surgical incisions or laceration repair.
Study NCT02460172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steel Staples
Description: Skin closure device for the closure of the skin layer following surgical incision
Study NCT04485936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epitomee Device
Description: medical Device designed to enhance the feeling of early satiation and prolonged satiety
Study NCT03616249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep
Description: Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.
Study NCT03616249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep
Description: Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.
Study NCT00023504 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
Study NCT03616249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: After these procedures, the sarcophagic elderly will Resistance training, will be performed according to the latest positioning of the American College of Sports Medicine for the training of the elderly . The training will last 12 weeks, 3 times / week, with intervals of 48h between the training sessions, which will have a maximum duration of 60min. The periodization of the training will be done in a linear way, in which the volunteers will be submitted to training with 1 series of 12 to 15 repetitions at 60% of 1RM in the first week; In the second week volunteers will train at 70% of 1RM, performing 2 sets of 10 to 12 repetitions; And from the third week to the end of the training period the volunteers will train at 80% of 1RM performing 3 sets of at most 8 replicates and the intervals between sets may range from 60min to 180min. The training load will be readjusted in the 6th week of training from a new 1RM test and the training will be on the same test equipment.
Study NCT03887052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASSURE™ Wearable Cardioverter Defibrillator (WCD)
Description: WCD with shock alarms and shock functionality disabled
Study NCT00597532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy
Description: soy (soy protein supplementation 50 grams/day)
Study NCT00597532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk
Description: placebo (milk protein supplementation 50 grams/day)
Study NCT04803890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-Touch Radiofrequency Ablation
Description: No-Touch Radiofrequency Ablation Using Octopus Electrodes and Combined RF Energy Delivery Mode
Study NCT04189380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLQ (Health literacy questionnaire)
Description: each patient complete survey and self-assessment questionnaire before or after his medical consultation
Study NCT04189380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MoCA (Montreal Cognitive Assessment)
Description: each patient complete survey and self-assessment questionnaire before or after his medical consultation
Study NCT02545972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus extended release
Description: daily dosing of tacrolimus
Study NCT00023504 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus diphtheria toxoid
Description: To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
Study NCT03791489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariFix
Description: The ClariFix™ device (K162608) is an FDA 510(k) cleared Class II cryosurgical tool indicated for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
Study NCT02503735 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir/Ledipasvir FDC
Description: 12 weeks treatment with Harvoni
Study NCT01740947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
Description: SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
Study NCT04648553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-Based Grounding
Description: Three 50 minutes sessions with an interventionist that includes 6 non-punitive components of treatment common in Behavioral Parent Trainings: Education on behavior change, positive one-on-one time between parents and their children, differential attending to positive and negative behaviors, effective praise, giving effective instructions, and using a point and reward system to encourage prosocial behaviors. These components are distilled into 5 skill modules and paired with Task-Based Grounding, which involves a brief restriction of privileges and provides children with the opportunity to end the restriction by completing a prosocial task.
Study NCT04648553 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Connected Care (Enhanced Treatment as usual)
Description: Two sessions with a facilitator. The facilitator does NOT provide any guidance to the parent on managing their child's behavior, but provides empathy and problem solving to help them find a resource that best fits their needs. It is particularly geared towards helping parents connect with Behavioral Parent Trainings to address the needs of children with oppositional, defiant, or aggressive behaviors.
Study NCT02160574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.
Study NCT02160574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Sodium Lauryl Sulfate
Description: The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.
Study NCT01836367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate 0.015%
Description: Picato